Company Patenting Tech for Designing Babies
By John Fowler,
KTVU
| 11. 20. 2013
[With CGS's Marcy Darnovsky]
BERKELEY, Calif. — Parents will do just about anything to improve what they see as their children’s chance for success. But does that mean biotechnology?
Some say boosting a child’s chances before conception is ‘creepy’.
But what is wrong with a more perfect baby? One where you pick the eye color, athletic ability and disease risk?
“I guess if you could eliminate that (disease risk) that’s a pretty good thing,” said Tom Robarge of San Francisco.
Though Narkee Rosenberg said “it’s a little like playing with fate and future, and I don’t know how I feel 100 percent about that”.
Biotechnology may now give parents unprecedented choices.
“Our understanding of genetics in the last ten years has really exploded,” said 23andme scientist Emily Conley.
Fertility clinics already use pre-implantation genetic diagnosis, PGD, to select traits for some in-vitro babies. But intentional manipulation might create ethical nightmares such as in the sci-fi film GATTACA where genetics means success.
Marcy Darnovsky from the Center for Genetics and Society in Berkeley is very concerned of this possibility.
“A world of genetic haves and...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...